Ex vivo IFN-γ ELISpot statistics (1): comparison of screening, week 1 and week 24 responses within low- and high-dose groups, for both summed and single pooled peptides, using the Wilcoxon signed rank test
| Dose | Screening (n=10) | Week 1 (n=10) | Week 24 (n=10) |
| Summed pooled peptides—within-dose changes from screening to peak and plateau | |||
| Low | |||
| Median (range) | 10 (3–20) | 738 (109–4398) | 20 (0–237), n=9 |
| Median difference (range) (compared with screening) | 730 (109–4383) | 17 (−8–218), n=9 | |
| p Value* | 0.007 | 0.17 | |
| High | |||
| Median (range) | 3 (0–14) | 1730 (758–2138) | 42 (33–256) |
| Median difference (range) (compared with screening) | 1721 (743–2135) | 42 (27–247) | |
| p Value* | 0.005 | 0.007 | |
| Single pooled peptides—within-dose changes from screening to peak and plateau | |||
| Low | |||
| Median (range) | 0 (0–8), n=9 | 393 (67–1275), n=9 | 13 (2–103), n=9 |
| Median difference (range) (compared with screening) | 393 (60–1272), n=9 | 13 (2–97), n=9 | |
| p Value* | 0.009 | 0.032 | |
| High | |||
| Median (range) | 0 (0–8) | 502 (312–677) | 14 (0–68) |
| Median difference (range) (compared with screening) | 502 (294–677) | 14 (0–66) | |
| p Value* | 0.005 | 0.048 | |
↵* Wilcoxon signed rank test.